What Джинтропин Treats: Main Uses and Benefits

The therapeutic uses of Джинтропин (Jintropin), which contains the active substance somatropin, is relevant for easing symptoms linked to a lack of the body's natural growth hormone in various contexts.

This medicine is used to manage symptoms in conditions such as growth hormone deficiency (GHD) in both children and adults, and to address growth failure associated with specific syndromes like Turner syndrome or Prader-Willi syndrome. It is also applied in settings that involve severe physical wasting. The use is applied across domains where additional symptomatic support is needed to help manage related physical and systemic symptoms.

Supporting Growth and Vitality

In children, this medication is a supportive therapy for insufficient growth symptoms, which generally helps support the attainment of an appropriate adult height. In adults, it is used to manage symptoms of systemic imbalance by assisting with functional stability, which may contribute to improved day-to-day comfort and physical well-being. This is applied in scenarios where additional management of discomfort is required.

Quick Fact: Addressing Body Composition Symptoms This medication helps address symptom clusters related to systemic imbalance, such as changes in muscle and fat distribution, associated with growth hormone deficiency.

“The use is applied across domains where additional symptomatic support is needed to help manage related physical and systemic symptoms.”

Regulatory References

1. European Medicines Agency therapeutic overview

Who Can and Cannot Use Джинтропин (Somatropin)

The eligibility for using Джинтропин is strictly determined by regulatory rules that define the allowed patient groups and absolute exclusions.

Populations for Whom Use is Contraindicated

The medicine is absolutely prohibited for specific populations, as defined in official labeling. This includes patients with any active malignancy or who are acutely critically ill following major trauma, open heart, or abdominal surgery. Use is also contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy, and for growth promotion in pediatric patients whose growth plates (epiphyses) are closed

. Additionally, children with Prader-Willi Syndrome who have severe respiratory impairment must not use Somatropin.

Age-Related and Conditional Eligibility

Age Eligibility is established for pediatric patients up until epiphyseal closure and for adults with confirmed growth hormone deficiency. Older adults (65 years and over) may be eligible but are advised to start with lower doses due to potential increased sensitivity.

Conditional Restrictions apply to certain health conditions:

Interactions with other medicines and products

The interaction profile of Джинтропин (Somatropin) is defined by its effects on hormonal regulation and metabolic pathways, requiring potential dose adjustments for co-administered medicines. The official regulatory documents classify these as clinically significant interactions. No formal drug-drug combinations are specified as contraindicated.

Population-Specific Interaction Considerations

In pediatric patients, concurrent use of pharmacologic doses of glucocorticoids may attenuate the growth-promoting effects of Somatropin. Careful management of glucocorticoid replacement dosing is required to mitigate this effect. This profile strictly details label-based interaction facts and does not include therapeutic instructions or general safety summaries.

Джинтропин is a recombinant human growth hormone. The active ingredient functions as an agonist, binding to specific growth hormone receptors (GHRs) located on the surface of target cells, including hepatocytes and muscle cells. This interaction initiates a conformational change in the receptor structure. The binding event subsequently activates the associated JAK-STAT signaling pathway within the cytoplasm. This resultant intracellular cascade upregulates gene transcription in the cell nucleus, which leads to an increased production of insulin-like growth factor-1 (IGF-1) in the liver and other tissues. The secreted IGF-1 then acts endocrinologically and locally to modulate cellular activity through the IGF-1 receptor. This signaling cascade promotes protein synthesis in skeletal muscle and modulates cellular processes involved in skeletal tissue formation, specifically influencing chondrocyte proliferation and differentiation within the growth plates. The mechanism further influences adipose tissue lipolysis and modulates overall bone mineral metabolism at a systemic level.

Джинтропин, which contains the active substance somatropin, is a medicine administered strictly by subcutaneous injection (SC) on a once-daily schedule; it is not to be injected intravenously. The medicine is supplied in formulations that may require reconstitution, such as lyophilized powder, and the resulting solution must be visually inspected to ensure it is clear and colorless before use.

Dosing is highly individualized and managed under the supervision of a specialized physician. For adults with Growth Hormone Deficiency (GHD), therapy typically begins with a non-weight-based starting dose, often in the range of 0.15 mg/day to 0.30 mg/day. This starting dosage is not fixed, but is gradually adjusted—or titrated—by small increments every 1-2 months according to individual patient requirements.

Specific administration rules govern its long-term use. The injection site must be rotated daily (e.g., using the thigh, abdomen, or buttocks) to mitigate the risk of localized tissue changes. Furthermore, specific guidelines apply for certain populations: patients over 60 years of age, for example, are instructed to begin therapy with a lower starting dose, and treatment for pediatric patients must be discontinued once their epiphyseal growth plates have fused. The overall regimen is structured as a long-term replacement protocol, demanding constant, gradual adjustment rather than a fixed treatment cycle.

Evidence for Pediatric Growth Hormone Deficiency (GHD)

Research into Somatropin for pediatric GHD relies on short-term controlled studies and extensive long-term observational registries. The studies primarily monitor children and adolescents with confirmed GHD, examining changes in linear growth, measured by Height Velocity and Height Standard Deviation Score (HSDS).

Short-term trials described patterns of changes in growth measurements. The evidence base for this population is extensive, according to regulatory assessments. However, definitive long-term outcomes for adult health markers, such as cardiovascular events or mortality, are not fully established by dedicated Randomized Controlled Trials (RCTs) and rely primarily on observational follow-up.

Evidence for Adult Growth Hormone Deficiency (GHD)

The use of Somatropin in adults with confirmed GHD was evaluated in double-blind, placebo-controlled RCTs and international registries. Research explored outcomes related to systemic imbalance, measuring changes in body composition (Lean Body Mass and Total Body Fat), metabolic markers, and patient-reported Quality of Life (QoL) scores.

Research related to body composition changes is extensive, according to regulatory assessments, but data for very long-term clinical outcomes are still emerging. Reliance on observational data limits insight into the maintenance of effects over many years.

Research Landscape and Uncertainties

Research also explored Somatropin in specific pediatric populations with confirmed conditions, including Turner Syndrome and Prader-Willi Syndrome (PWS), where RCTs measured changes in growth and body composition. Studies were also conducted for Short Stature following Small for Gestational Age (SGA) and Idiopathic Short Stature (ISS), where the evidence base is generally moderate and findings on final height measurement were described as mixed.

Overall, the evidence landscape provides context but not individual predictions. Long-term effects are not fully established; there is limited information for clinical outcomes that may take decades to manifest. Data for certain subgroups remain insufficient, and research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Key Studies & References

1. Endocrine Society Clinical Practice Guideline on Growth Hormone Deficiency (Representative Guideline)
2. Systematic Review and Meta-analysis of Somatropin Efficacy in Pediatric Growth Disorders (Representative Evidence Synthesis)

Common questions about Джинтропин (FAQ)

Q: What is Джинтропин (Jintropin) and what is it used for?

Джинтропин (Jintropin) is a brand name for the medication recombinant human growth hormone (also known as somatropin). It is a synthetic form of the growth hormone naturally produced by the pituitary gland.

It is used to treat children and adults who have a growth hormone deficiency (GHD). In children, this deficiency can lead to growth failure and short stature. In adults, it can be used to treat GHD that began either in childhood or adulthood, often resulting from pituitary gland disease, radiation therapy, surgery, or trauma.

It is also approved for the treatment of:

• Children with Prader-Willi syndrome.
• Children who are small for gestational age (SGA) and fail to show catch-up growth by age 2.
• Children with Turner syndrome.
• Children with Idiopathic Short Stature (ISS).
• Adults with HIV-associated wasting or cachexia (muscle loss).

Q: How is Джинтропин administered?

Джинтропин is administered via subcutaneous injection, which means it's injected just under the skin.

It typically comes as a powder that must be mixed (reconstituted) with a specific liquid (diluent) before use. It must never be injected intravenously (into a vein) or intramuscularly (into a muscle).

The most common sites for subcutaneous injection are the thigh, abdomen, and upper arm. It is important to rotate the injection site each day to avoid tissue breakdown (lipoatrophy) at the injection area.

Q: How does Джинтропин work?

Джинтропин works by replacing the growth hormone that the body is not producing enough of. When injected, the somatropin molecule binds to specific receptors on cells throughout the body, primarily in the liver. This binding stimulates the liver to produce insulin-like growth factor-1 (IGF-1).

IGF-1 is the primary mediator of the effects of growth hormone. It travels through the bloodstream to target tissues where it promotes:

• Growth in children: It stimulates the growth of bones, particularly at the growth plates (epiphyses), leading to increased height.
• Metabolism: It influences the metabolism of proteins, carbohydrates, and lipids.
• Body composition: In adults, it helps maintain lean body mass and reduce body fat.

Q: What are the potential side effects of taking Джинтропин?

Like all medicines, Джинтропин can cause side effects, although not everyone gets them. Side effects can vary between children and adults.

Common side effects may include:

• Injection site reactions: Pain, redness, swelling, or rash at the injection area.
• Fluid retention (edema): Swelling, especially in the hands and feet, or joint pain. This is more common in adults and usually temporary.
• Headache.
• Muscle and joint pain (arthralgia).

Less common but serious side effects include:

• Increased intracranial pressure (pseudotumor cerebri), which may cause persistent, severe headache, vision problems, and nausea.
• Slipped capital femoral epiphysis (in children, a hip disorder).
• Pancreatitis (inflammation of the pancreas).
• Changes in blood sugar (glucose) levels, as growth hormone can affect insulin sensitivity.
• Hypothyroidism (underactive thyroid gland).

Any persistent or severe side effects should be reported to a healthcare provider.

Q: How should Джинтропин be stored?

Proper storage is critical to ensure the medication remains effective. Storage instructions depend on whether the product is in a powder (unreconstituted) or liquid (reconstituted) form.

• Before Mixing (Powder): The powder vials should typically be stored in a refrigerator, protected from light, at a temperature range of 2°C to 8°C (36°F to 46°F). They should not be frozen.
• After Mixing (Liquid): Once reconstituted with the diluent, the liquid solution must be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. The solution is only stable for a certain period after mixing, usually 14 to 28 days, depending on the specific product instructions.

Do not use the solution if it appears cloudy or contains particles.

Q: Can Джинтропин be used by athletes to enhance performance?

No, the use of Джинтропин (somatropin) for athletic performance enhancement is generally prohibited by major sports organizations (such as the World Anti-Doping Agency - WADA) and is considered a form of doping.

Using growth hormone when the body does not have a medical deficiency is not medically recommended and can carry significant health risks, including potential for serious side effects like joint pain, fluid retention, carpal tunnel syndrome, and an increased risk of certain metabolic disorders.

Джинтропин is a prescription medication intended strictly for the treatment of specific medical conditions diagnosed by a doctor.

How to Store and Dispose of Джинтропин?

The storage and disposal instructions for somatropin (Джинтропин) are strictly defined by regulatory labeling to maintain product stability.